Related Experiment Video
Updated: Aug 7, 2026
12:13
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
New molecular targets in advanced prostate cancer
1Marlene and Stewart Greenebaum Cancer Center, University of Maryland, 22 South Greene Street, Baltimore, MD 21201-1595, USA. ndawson@umm.edu
Expert Review of Anticancer Therapy
|July 13, 2006
Summary
New prostate cancer therapies show promise beyond traditional treatments. Novel strategies targeting molecular pathways and utilizing immunotherapy, like APC8015 (Provenge), are improving survival rates for advanced prostate cancer.
Area of Science:
- Oncology
- Urology
- Molecular Biology
Background:
- Advanced prostate cancer treatment historically relies on hormonal therapy and chemotherapy, offering survival benefits but not a cure.
- Understanding prostate cancer pathophysiology has spurred development of novel molecular targets and therapeutic strategies.
- This review highlights promising new approaches for advanced and localized prostate cancer.
Purpose of the Study:
- To review and discuss the most promising novel therapeutic strategies for advanced prostate cancer.
- To explore emerging molecular targets and their clinical applications.
- To provide an overview of recent advancements in prostate cancer treatment.
Main Methods:
- Review of current literature on novel prostate cancer therapies.
- Focus on specific emerging strategies including endothelin pathway antagonists, vaccine therapy, and antisense oligonucleotides.
- Analysis of clinical trial data for immunotherapies like APC8015 (Provenge).
Main Results:
- The endothelin pathway is implicated in bone tumorigenesis, leading to endothelin receptor antagonist development.
- Autologous granulocyte-macrophage colony-stimulating factor-producing prostate cancer cell vaccine therapy elicits immune and clinical responses.
- Randomized trials of APC8015 (Provenge) show improved survival in hormone-refractory prostate cancer.
- Antisense oligonucleotides targeting mRNA critical for androgen-independent disease are under investigation.
Conclusions:
- Significant progress is being made in developing novel therapies for prostate cancer.
- Emerging strategies offer new hope for improving outcomes in this prevalent disease.
- A combination of approaches targeting molecular pathways and utilizing immunotherapy is expanding treatment options.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: